

Update: Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective May 1, 2014, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- **Cymbalta, Evista and Mepron will be added** to the program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- **Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.**
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

List of Brand Name Drugs included in this program* (Updated 4/17/14):

Accolate	Evista	Sanctura XR
Adderall XR	Felbatol	Solaraze
Alphagan P 0.15%	Focalin XR(15mg,30mg,45mg)	Soriatane
Astelin	Gabitril 2mg, 4mg	Symbyax
Bactroban cream	Hepsera	Tegretol suspension
Carbatrol	Kadian	Tegretol XR
Catapres-TTS	Lidoderm	TOBI
Combivir	Lovenox	Tobradex
Cymbalta	Marinol	Toprol XL
Depakote sprinkle	Mepron	Tricor
Dovonex Cream	Myfortic	Trileptal suspension
Diastat	Niaspan	Trilipix
Diovan HCT	Prandin	Trizivir
Duetact	Prevpac	Vancocin
Epivir	Prograf	Valtrex
Epivir HBV	Pulmicort Respules	Ziagen tablet

*List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.